echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Nature Medicine: Complications increase plasma biomarker levels associated with Alzheimer's disease

    Nature Medicine: Complications increase plasma biomarker levels associated with Alzheimer's disease

    • Last Update: 2022-08-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    A simple blood test to diagnose Alzheimer's disease is an exciting possibility, perhaps even years before symptoms appear, but a new study suggests that before these blood tests are routinely used in clinical diagnostic settings , more research is need.


    The research is published in the latest online edition of Nature Medici.


    Two hallmarks of Alzheimer's disease are tau tangles and beta-amyloid plaqu.


    "Blood biomarkers are targets for screening and diagnosis of Alzheimer's disease because they are less expensive and more invasive, but we need to understand these biomarkers in community populations before they can be used clinical.


    Phosphorylated tau181 and 217 (p-tau181 and p-tau217), two blood markers, are expected to be new specific biomarkers for Alzheimer's disease and may provide new insights into the screening or detection of Alzheimer's disease in the general population w.


    "Before these blood-based biomarkers enter clinical use, it is critical that we establish reference ranges that understand differences in age, sex and underlying health conditio.


    In the study, researchers tested 1,329 participants, ages 30 to 98, with p-tau181 and p-tau217 through the Mayo Clinic study of Aging to assess the effects of PET imaging on Diagnostic role of p-tau181 and p-tau217, which are predictors of elevated brain beta-amyloid and tau tangl.


    The researchers found that while p-tau181 and p-tau217 increased with age, the increase occurred primarily in people who were amyloid-positive, suggesting that these biomarkers are specific for Alzheimer's disease rather than Other neurodegenerative diseases provide additional eviden.


    The study's findings also confirmed that plasma p-tau181 and p-tau217 were predictors of elevated brain amyloid and tau, as measured by PET imaging, but the results were not as good as reported by patients previously seen in specialized memory clinics Go.


    "More research needs to be done in larger studies, especially in more diverse populations," Milk sa.


    article title

    Performance of plasma phosphorylated tau 181 and 217 in the community

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.